Molecular Profile Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G12S lung cancer decreased response MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Trametinib Preclinical Actionable In a preclinical study, a lung adenocarcinoma cell line harboring KRAS G12S demonstrated a decreased response when treated with Mekinist (trametinib) in culture (PMID: 26582713). 26582713
KRAS G12S non-small cell lung carcinoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Pimasertib + Regorafenib Preclinical - Cell culture Actionable In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727). 23629727
KRAS G12S non-small cell lung carcinoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Pimasertib + Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727). 23629727
KRAS G12S pancreatic cancer sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Binimetinib Preclinical Actionable In a preclinical study, pancreatic cell lines with KRAS codon 12 mutations had increased sensitivity to Binimetinib (MEK162) (PMID: 25167228). 25167228
KRAS G12S lung cancer sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor APS-2-79 + Trametinib Preclinical - Cell culture Actionable In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948). 27556948
KRAS G12S lung adenocarcinoma sensitive Afatinib Preclinical - Cell line xenograft Actionable In a preclinical study, lung adenocarcinoma cells harboring KRAS G12S were sensitive to treatment with Gilotrif (afatinib), demonstrating decreased cell proliferation and reduced Erk, Mek, and Akt activity in culture, and decreased tumor growth in cell-line xenograft models (PMID: 29925635). 29925635
KRAS G12S lung carcinoma sensitive AZD4785 AZD4785 Preclinical - Cell culture Actionable In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of lung carcinoma cells harboring KRAS G12S (PMID: 28615361). 28615361
KRAS G12S colorectal cancer resistant Sunitinib Preclinical Actionable In a preclinical study, a colorectal cancer cell line harboring the KRAS G12S mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880). 23455880
KRAS G12S lung cancer sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor APS-2-79 + Binimetinib Preclinical - Cell culture Actionable In a preclinical study, the combination of APS-2-49 and Binimetinib (MEK162) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948). 27556948
KRAS G12S lung adenocarcinoma no benefit Gefitinib Preclinical - Cell culture Actionable In a preclinical study, lung adenocarcinoma cells harboring KRAS G12S were insensitive to treatment with Iressa (gefitinib) in culture, demonstrating minimal inhibition of cell growth (PMID: 29925635). 29925635
KRAS G12S non-small cell lung carcinoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Navitoclax + Trametinib Preclinical Actionable In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 25665005). 25665005
KRAS G12S lung adenocarcinoma decreased response MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Binimetinib Preclinical - Cell culture Actionable In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12S mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710). 27422710
KRAS G12S lung adenocarcinoma decreased response MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Selumetinib Preclinical - Cell culture Actionable In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12S mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710). 27422710
KRAS G12S non-small cell lung carcinoma sensitive TAE226 Preclinical Actionable In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring KRAS G12S mutation in culture (PMID: 26090892). 26090892
KRAS G12S lung cancer sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor APS-2-79 + Selumetinib Preclinical - Cell culture Actionable In a preclinical study, the combination of APS-2-49 and Selumetinib (AZD6244) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948). 27556948
KRAS G12S lung adenocarcinoma no benefit Erlotinib Preclinical - Cell line xenograft Actionable In a preclinical study, lung adenocarcinoma cells harboring KRAS G12S were insensitive to treatment with Tarceva (erlotinib) in culture, demonstrating no change in Erk, Mek, and Akt activity and minimal inhibition of cell growth (PMID: 29925635). 29925635
KRAS G12S non-small cell lung carcinoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Trametinib + TW-37 Preclinical Actionable In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 25665005). 25665005
KRAS G12S non-small cell lung carcinoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Everolimus + Pimasertib Preclinical - Cell culture Actionable In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727). 23629727
KRAS G12S lung cancer decreased response MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor PD-0325901 Preclinical Actionable In a preclinical study, a lung cancer cell line harboring KRAS G12S demonstrated a decreased response when treated with PD-0325901 in culture (PMID: 26582713). 26582713
KRAS G12S non-small cell lung carcinoma sensitive PI3K Inhibitor (Pan) Gedatolisib Preclinical Actionable In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring KRAS G12S in culture (PMID: 21325073, PMID: 23012248). 21325073 23012248
KRAS G12S lung cancer predicted - resistant RMC-4550 Preclinical - Cell culture Actionable In a preclinical study, RMC-4550 did not inhibit growth of lung cancer cells harboring KRAS G12S in 3D culture (PMID: 30104724). 30104724
KRAS G12S lung cancer decreased response MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Refametinib Preclinical Actionable In a preclinical study, a lung adenocarcinoma cell line harboring KRAS G12S demonstrated a decreased response when treated with Refametinib (BAY86-9766) in culture (PMID: 26582713). 26582713
KRAS G12S lung cancer sensitive PI3K Inhibitor (Pan) Rigosertib Preclinical - Cell line xenograft Actionable In a preclinical study, Estybon (rigosertib) inhibited Mek/Erk signaling and tumor growth in cell line xenograft models of lung cancer harboring KRAS G12S (PMID: 27104980). 27104980
KRAS G12S lung cancer sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor APS-2-79 + PD-0325901 Preclinical - Cell culture Actionable In a preclinical study, the combination of APS-2-49 and PD-0325901 worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948). 27556948
Clinical Trial Phase Therapies Title Recruitment Status